SF-295

SF-295 is a human glioblastoma cell line derived from a left frontal lobe tumor of a 67-year-old Caucasian female patient. These cells exhibit glial-like morphology and are hypertriploid, with a near-pentaploid chromosome number ranging from 104 to 126. They are homozygous for mutations in tumor suppressor genes PTEN and TP53 and possess a TERT promoter mutation (C228T), commonly associated with glioblastoma multiforme (GBM). SF-295 cells lack expression of glial markers GFAP and glutamine synthetase but express neurofibromin-1 (NF1). In vivo studies have shown that SF-295 cells are non-tumorigenic in athymic mice. This cell line has been extensively utilized in preclinical research, including studies on chemotherapeutic agents like temozolomide and BCNU, where it demonstrated significant tumor growth delay and synergistic effects when used in combination therapies. SF-295 is also part of the NCI-60 cancer cell line panel, making it a valuable model for investigating GBM biology and therapeutic responses.